HELLS serves as a poor prognostic biomarker and its downregulation reserves the malignant phenotype in pancreatic cancer

Table 2 SMARCAs transcription levels between pancreatic cancer and normal tissues (ONCOMINE)

	Types of pancreatic cancer versus normal pancreatic tissue	Fold change	P value	t test	References
SMARCA2	Pancreatic ductal adenocarcinoma	− 6.555	0.009	3.107	Buchholz Pancreas [13]
SMARCA3	Pancreatic ductal adenocarcinoma	2.522	0.008	3.688	Buchholz Pancreas [13]
SMARCA4	Pancreatic adenocarcinoma	2.257	7.16E−4	4.459	Logsdon Pancreas [14]
HELLS	Pancreatic ductal adenocarcinoma	2.596	0.005	2.867	Grutzmann Pancreas [15]
	Pancreatic carcinoma	2.386	3.50E−8	6.352	Pei Pancreas [16]

Order by Over-expression: Fold Change; P value < 0.01; Fold Change > 2; Gene Rank: Top 10%

ISSN: 1755-8794